Literature DB >> 32739039

Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient.

Nouran Eshak1, Mahmoud Abdelnabi2, Somedeb Ball3, Emaneldeen Elgwairi3, Kendall Creed3, Victor Test3, Kenneth Nugent3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32739039      PMCID: PMC7366085          DOI: 10.1016/j.amjms.2020.07.022

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


× No keyword cloud information.
Dear Editor Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several neurological manifestations have been reported in these patients, ranging from mild symptoms, such as anosmia, hypogeusia, and headaches, to more severe manifestations, such as acute encephalitis, cerebrovascular stroke, polyneuropathy, and Guillian Barre syndrome (GBS). The involvement of the autonomic nervous system (ANS) in SARS-Cov-2 infection has not been reported. Dysautonomia, defined as the failure or sometimes overactivity of the sympathetic or parasympathetic components of the ANS, has a wide range of clinical manifestations, including labile blood pressure, orthostatic hypotension, impotence, bladder dysfunction, and alterations in bowel functions. It can be acute or chronic and reversible or progressive and has been reported with diverse medical conditions, such as diabetes mellitus, alcoholism, GBS, and Parkinson's disease. Acute dysautonomia has also been reported with viral infections, such as mumps, HIV, hepatitis C virus, Epstein-Barr virus, and Coxsackie B virus. Here, we report a case of dysautonomia, secondary to SARS-CoV-2 infection. We will demonstrate this phenomenon by illustrating blood pressure fluctuations and vasopressor requirements throughout 16 days of the patient's ICU stay. A 72-year-old man was referred from a nursing home for fever and worsening shortness of breath that started a week prior. His-past medical history included diabetes mellitus, hypertension, chronic obstructive pulmonary disease, coronary artery disease, diastolic heart failure, and sick sinus syndrome treated with a permanent pacemaker. He tested positive for COVID-19, and on admission to the ICU, he was hypoxemic with no improvement on high flow oxygen therapy or non-invasive ventilation. On the first hospital day, the patient was intubated and sedated using propofol. Blood cultures and respiratory cultures were drawn. Lower respiratory polymerase chain reaction (PCR) showed Staphylococcus aureus that was mecA negative, and the patient was started on cefazolin for seven days. No growth was shown on cultures later on. Baseline electrocardiogram (ECG) showed a paced rhythm, and transthoracic echocardiogram (TTE) showed a mildly reduced left ventricular ejection fraction (LVEF) of 45–49% and a grade II diastolic dysfunction. This ejection fraction was reduced from the previous TTE done one-month prior which showed a LVEF of 70% with left ventricular hypertrophy. From day one to day 14, prone positioning for 16 h per day was done, and he was sedated and paralyzed using propofol, fentanyl, and rocuronium. He initially had good urine output on furosemide; however, due to progressive renal failure, he required hemodialysis on hospital day 6, and this was continued every other day throughout his hospital stay. On day 13 the patient's troponin trended up, serial ECGs did not show ST-segment elevations or depressions, and repeat TTE showed a mild reduction of LVEF to 40–44% with no regional wall motion abnormalities. COVID myocarditis was suspected, but no cardiac catheter or further imaging studies were done due to the patient's critical condition. On day 14, the patient developed fever, pan-cultures were done which later showed no growth, no antibiotics were initiated, and inflammatory markers continued to trend down. Of note, the patient had a depressed cough and gag reflexes on tracheal suctioning during mechanical ventilation. A week later, with no sustained improvement and the inability to wean him off the ventilator, the patient's family decided to stop ventilatory support and to pursue comfort care. Throughout his hospitalization, the patient was noted to have labile blood pressures, with intermittent, varying vasopressor requirements (norepinephrine and/or vasopressin) (Figure 1 ). These blood pressure fluctuations were noted throughout the day, especially when changing positions from prone to supine or vice versa. Sepsis was ruled out with no growth in cultures, and he had a consistently negative procalcitonin throughout the hospital course and a downward trend in inflammatory markers (Figure 2 ). Efforts were made to maintain a euvolemic state, and his overall fluid balance throughout hospital stay was a positive 1.7 liters, which would not explain hypertensive or hypotensive episodes.
Figure 1

Heart rate in beats per minute from day 1 through day 16 and the mean blood pressure and millimeters of mercury from day 1 through day 16. The horizontal bars in the mean arterial pressure figure represent periods of time requiring vasopressors.

Figure 2

Values for ferritin, C-reactive protein (CRP), procalcitonin, and troponin on hospital days 1 through 16.

Heart rate in beats per minute from day 1 through day 16 and the mean blood pressure and millimeters of mercury from day 1 through day 16. The horizontal bars in the mean arterial pressure figure represent periods of time requiring vasopressors. Values for ferritin, C-reactive protein (CRP), procalcitonin, and troponin on hospital days 1 through 16. His-fluctuating blood pressure could be explained by acute dysautonomia through afferent baroreflex failure, a syndrome characterized by highly labile blood pressures with hypertensive crises alternating with hypotensive episodes; orthostatic hypotension is occasionally present. The mechanism involves damage to the afferent baroreceptor pathway, starting from baroreceptors in carotid bodies to the vagal and glossopharyngeal nerve fibers, and finally to the nucleus tractus solitaries (NTS). It can occur secondary to neck irradiation or surgery, and more rarely, in tumors of the NTS. , Studies have shown that SARS-COV-2 affects the central nervous system, with a high affinity to the medullary structures, including the ventrolateral medulla and the NTS, as these areas have a strong ACE2 expression. We suggest that acute dysautonomia in the form of hemodynamic instability seen with critically ill COVID-19 patients may be explained by afferent baroreflex failure secondary to SARS-COV-2 infection and invasion of the NTS. It is important to optimize blood pressure management in these patients. Hypotension is not necessarily a sign of septic shock, especially if unsupported by other clinical signs of sepsis, inflammatory markers, and cultures. We recommend maintaining a euvolemic state and avoiding excessive fluid resuscitation during hypotensive episodes with gradual titration of vasopressors to avoid overshooting blood pressures and using short-acting anti-hypertensive medications in hypertensive crisis.
  24 in total

1.  Observational case series of postural tachycardia syndrome (PoTS) in post-COVID-19 patients.

Authors:  Nicholas P Gall; Stephen James; Lesley Kavi
Journal:  Br J Cardiol       Date:  2022-01-26

Review 2.  Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies.

Authors:  Francisco Carmona-Torre; Ane Mínguez-Olaondo; Alba López-Bravo; Beatriz Tijero; Vesselina Grozeva; Michaela Walcker; Harkaitz Azkune-Galparsoro; Adolfo López de Munain; Ana Belen Alcaide; Jorge Quiroga; Jose Luis Del Pozo; Juan Carlos Gómez-Esteban
Journal:  Front Neurol       Date:  2022-05-27       Impact factor: 4.086

3.  Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study.

Authors:  Irene Scala; Simone Bellavia; Marco Luigetti; Valerio Brunetti; Aldobrando Broccolini; Maurizio Gabrielli; Lorenzo Zileri Dal Verme; Paolo Calabresi; Giacomo Della Marca; Giovanni Frisullo
Journal:  Neurol Sci       Date:  2022-05-24       Impact factor: 3.830

4.  Autoimmune gastrointestinal dysmotility following SARS-CoV-2 infection successfully treated with intravenous immunoglobulin.

Authors:  Mayra Montalvo; Padmini Nallapaneni; Sara Hassan; Samuel Nurko; Sean J Pittock; Julie Khlevner
Journal:  Neurogastroenterol Motil       Date:  2022-01-04       Impact factor: 3.960

5.  A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine.

Authors:  Sujana Reddy; Satvik Reddy; Manish Arora
Journal:  Cureus       Date:  2021-05-04

6.  Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients.

Authors:  Hadar Klein; Kim Asseo; Noam Karni; Yuval Benjamini; Ran Nir-Paz; Mordechai Muszkat; Sarah Israel; Masha Y Niv
Journal:  Clin Microbiol Infect       Date:  2021-02-16       Impact factor: 8.067

7.  Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies.

Authors:  William T Gunning; Stanislaw M Stepkowski; Paula M Kramer; Beverly L Karabin; Blair P Grubb
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

8.  Clinical characterization of dysautonomia in long COVID-19 patients.

Authors:  Nicolas Barizien; Morgan Le Guen; Stéphanie Russel; Pauline Touche; Florent Huang; Alexandre Vallée
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

Review 9.  New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.

Authors:  Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan
Journal:  J Neurol       Date:  2020-10-12       Impact factor: 4.849

Review 10.  A clinical primer for the expected and potential post-COVID-19 syndromes.

Authors:  Brian Walitt; Elizabeth Bartrum
Journal:  Pain Rep       Date:  2021-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.